市場調査レポート
商品コード
1226606
ザラコール薬品の考察と市場予測(2032年)XARACOLL Drug Insight and Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
ザラコール薬品の考察と市場予測(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
当レポートでは、米国のザラコール薬品市場について調査分析し、作用機序、用法と用量、研究開発活動についての考察や、市場予測などを提供しています。
"XARACOLL Drug Insight and Market Forecast - 2032" report provides comprehensive insights about XARACOLL for Postoperative Pain in the United States. A detailed picture of the XARACOLL for Postoperative Pain in the United States for the study period 2019-2032 is provided in this report along with a detailed description of the XARACOLL for Postoperative Pain. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XARACOLL market forecast, analysis for Postoperative Pain in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative Pain.
XARACOLL (bupivacaine HCl) implant is a unique, non-injectable drug-device combination in the form of a fully bioresorbable collagen implant containing bupivacaine hydrochloride that provides postsurgical pain relief through the delivery of bupivacaine, a local anesthetic, at the surgical site. XARACOLL is placed directly into the surgical site during surgery and, after placement, releases bupivacaine immediately and over time.
XARACOLL was approved in August 2020 by the US Food and Drug Administration (FDA). XARACOLL is indicated in adults for placement into the surgical site to produce postsurgical local analgesia for up to 24 h following open inguinal hernia repair. The drug contains a local amide anesthetic and is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 h following open inguinal hernia repair.
As per the company, XARACOLL is launched through a partnership between Mallinckrodt Pharmaceutical's Acute Care Sales Team and Innocoll's Hospital Sales Team.
Dosage and administration
The recommended dose is 300 mg bupivacaine HCl (three XARACOLL implants, each containing 100 mg bupivacaine HCl).
Mechanism of Action
Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve by slowing the propagation of the nerve impulse and reducing the rate of rise of the action potential. Clinically, the order of a loss of nerve function is (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
XARACOLL Analytical Perspective by DelveInsight
This report provides a detailed market assessment of XARACOLL in Postoperative Pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of XARACOLL in Postoperative Pain covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions